The Immune Monitoring Core will provide support for all four projects in this Program Project. The fourProjects involve treatment with monoclonal antibodies (mAb) or tumor vaccines. MAb (humanized orchimerized) or radiolabeled mAb efficacy may be diminished by development of antibodies against the mAb(HAHA). Some types of HAHA may be avoided by modifications in mAb design, requiring sensitive assaysfor identifying and determining the precise specificity of the HAHA. Cancer vaccine development must bebased on assays of immunogenicity that can guide the process of vaccine construction. In both cases,maximal benefit will result if these assays are standardized and are performed by a centralized, dedicatedfacility, permitting comparison between Projects and overtime. While serological assays are sufficient formonitoring mAb studies in Projects 1 and 2, assays of T-lymphocyte immunity will also be required and willbe the main focus for the vaccination studies in Aims 3 and 4. The emphasis is on providing assaycontinuity within and between the projects and between these projects and our previous experience. Aseries of standardized assays will be used to provide the P.l.s of the individual Projects with a firm basis forselecting monoclonal antibodies (mAbs) or vaccines for further study.
The Specific Aims are:
Aim 1 : Utilize standardized serologic assays for quantitating the antibody response to immune interventionsin this Program Project, and determine the effector functions of these antibodies.
Aim 2 : Utilize a series of standardized assays to quantitate the T-cell response after vaccination and todetermine the phenotype and effector functions of the responding T-cells. Identify the peptides recognizedby these T-cells.
Aim 3 : Utilize these centralized, standardized assays to provide continuity within and between the Projectsover time, and between these Projects and our previous experience.
Aim 4 : Continue to test and standardize new reagents or assays as they become available.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA033049-25
Application #
7728800
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-01
Project End
2010-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
25
Fiscal Year
2008
Total Cost
$125,000
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Casey, E; Bournazos, S; Mo, G et al. (2018) A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32:547-549
Budhu, Sadna; Schaer, David A; Li, Yongbiao et al. (2017) Blockade of surface-bound TGF-? on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal 10:
Alidori, Simone; Thorek, Daniel L J; Beattie, Bradley J et al. (2017) Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS One 12:e0183902
Scheinberg, David A; Grimm, Jan; Heller, Daniel A et al. (2017) Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol 46:66-73
Weber, Daniela; Jenq, Robert R; Peled, Jonathan U et al. (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:845-852
Mathias, M D; Sockolosky, J T; Chang, A Y et al. (2017) CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia 31:2254-2257
Chang, Aaron Y; Gejman, Ron S; Brea, Elliott J et al. (2016) Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther 16:979-87
Alidori, Simone; Akhavein, Nima; Thorek, Daniel L J et al. (2016) Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 8:331ra39
Alidori, Simone; Bowman, Robert L; Yarilin, Dmitry et al. (2016) Deconvoluting hepatic processing of carbon nanotubes. Nat Commun 7:12343

Showing the most recent 10 out of 289 publications